Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control

Medical Care

Volumn 45, Issue 4, 2007, Pages 315-321

  Schmittdiel, Julie ^a   Vijan, Sandeep ^b   Fireman, Bruce ^a   Lafata, Jennifer Elston ^c   Oestreicher, Nina ^a   Selby, Joe V ^a  

^a DIVISION OF RESEARCH   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Diabetes; QALYs; Quality; Quality adjusted life years

Indexed keywords

AGED; ARTICLE; DIABETES MELLITUS; FEMALE; HEALTH CARE QUALITY; HUMAN; INSURANCE; MALE; METHODOLOGY; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; UNITED STATES;

AGED; CALIFORNIA; DIABETES MELLITUS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; QUALITY ASSURANCE, HEALTH CARE; QUALITY INDICATORS, HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 34247588162     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000254582.85666.01     Document Type: Article

References (50)

1. Renders CM, Valk GD, Griffin SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings. Diabetes Care. 2001;24:182L-1833.
2. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004; 140:945-950.
3. Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Am Intern Med. 2002;136:565-574.
4. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: Translating evidence into action. Health Aff (Millwood). 2001;20:64-78.
5. Li R, Bodenheimer T, Simon J, et al. Organizational factors affecting the adoption of diabetes care management process in physician organizations. Diabetes Care. 2004;27:2312-2316.
6. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-2645.
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
8. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus. J Clin Endocrinol Metab. 1992;78:809A-812A.
9. Selby .TV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes mellitus in a managed care population. Diabetes Care. 1997;20:1396-1402.
10. Knight K, Badamgarav E, Henning JM, et al. A systematic review of diabetes disease management programs. Am J Manag Care. 2005;11: 242-250.
11. Fireman B, Bartlett J, Selby J. Can disease management reduce health costs by improving quality? Health Aff (Milhwood). 2004;23:63-75.
12. Selby .TV, Scanlon D, Lafata JE, et al. Determining the value of disease management programs. Jt Commission J Quality Safety. 2003;9:491-499.
13. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care. 2003;41:1173-1182.
14. Pogach LM, Rajan M, Aron DC. Comparison of weighted performance measurement and dichotomous thresholds for glycemic control in the Veteran's Health Administration. Diabetes Care. 2006;29:241-246.
15. Hurtado MP, Swift EK, Corrigan JM, for the Institute of Medicine, eds. Envisioning the National Healthcare Quality Report: Designing the National Healthcare Quality Report. Washington, DC: National Academy Press; 2001.
16. Landon BE, Normand SL, Blumenthal D, et al. Physician clinical performance assessment: prospects and barriers. JAMA. 2003;290:1183-1189.
17. Werner RM, Asch DA. The unintended consequences of publicly reporting quality information. JAMA. 2005;293:1239-1244.
18. Meyer J, Rybowski L, Eichler R. Theory and Reality of Value-Based Purchasing: Lessons from the Pioneers. Rockville, MD: Agency for Health Care Policy and Research; 1997. AHCPR Publication No. 98-0004.
19. Maio V, Goldfarb NI, Carter C, et al. Value-Based Purchasing: A Review of the Literature. The Commonwealth Fund; May 2003.
20. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519-2527.
21. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type II diabetes. Ann Intern Med. 1997;127:788-795.
22. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896.
23. Rosen AB, Hamel MB, Weinstein MC, et al. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
26. Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9. Ophthalmology. 1991;98:766-785.
27. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
28. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
29. Ballard DJ, Humphrey LL, Melton LJ 3rd, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes. 1988;37:405-412.
30. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med. 1989;111:788-796.
31. National Institutes of Health. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
32. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
33. Collins R, Armitage J, Parish S, et al, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
34. Kjeldsen SE, Hedner T, Jamerson K, et al. Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension. 1998;31:1014-1020.
35. United States Life Tables, 2000. NVSR Vol. 51, No. 3, 39 pp. (PHS) 2003-1120.
36. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993; 13:161-165.
37. Mathias SD, Bates MM, Pasta DJ, et al. Use of the Health Utilities Index with stroke patients and their caregivers. Stroke. 1997;28:1888-1894.
38. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409-1415.
39. Lawrence WF, Grist TM, Brazy PC, et al. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis. 1995;25:701-709.
40. Brown GC, Brown MM, Sharma S, et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18-24.
41. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Medical Decision Making. 1993;13:89-102.
42. Brown AF, Gregg EW, Stevens MR, et al. Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care. 2005;28:2864-2870.
43. Heisler M, Smith DM, Hayward RA, et al. Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care. 2003;41: 1221-1232.
44. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
45. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997; 20:725-734.
46. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes. JAMA. 2002;287:2542-2551.
47. Schlessinger L, Eddy DM. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003;26:3093-3101.
48. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract. 2000;50(Suppl 3):S57-S64.
49. Herman WH, Hoerger TJ, Brandle M, et al, for the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-232.
50. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford Medical Publications; 1987.